Filana Therapeutics (FLNA) AGM 2026 summary

Opening remarks and agenda

• Meeting held virtually to increase inclusivity and accessibility for stockholders.

• Business portion conducted first, followed by a Q&A session.

• Forward-looking statements highlighted, with risks and uncertainties noted.

Board and executive committee updates

• Introduction of board members and corporate officers, including new additions to the executive team.

• Dr. Angélique Bordey and Dr. Joseph Hulihan joined as SVP of Neuroscience and Chief Medical Officer, respectively.

Strategic initiatives and plans

• Focus on addressing FDA clinical hold on IND for TSC-related epilepsy program.

• Extensive preclinical experiments conducted to address FDA concerns.

• Collaboration with TSC Alliance and engagement with leading clinicians and trial sites.

• Confidence in moving forward based on successful animal models.